J. Goldman & Co’s Revolution Medicines RVMD Stock Holding History

J. Goldman & Co’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,179	Closed	-$811K	–	850
2025 Q4	$811K	Sell	10,179 -4,187	-29%	-$275K	0.02%	414
2025 Q3	$671K	Sell	14,366 -6,377	-31%	-$250K	0.02%	360
2025 Q2	$763K	Sell	20,743 -5,069	-20%	-$195K	0.02%	353
2025 Q1	$913K	Sell	25,812 -523	-2%	-$21.2K	0.02%	372
2024 Q4	$1.15M	Buy	+26,335	New	+$1.33M	0.03%	313
2023 Q4	–	Sell	-22,135	Closed	-$613K	–	460
2023 Q3	$613K	Buy	+22,135	New	+$657K	0.02%	265

Other funds holding RVMD

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

J. Goldman & Co's RVMD Position: Q1 2026 in Review

J. Goldman & Co sold out of Revolution Medicines (RVMD) in Q1 2026, closing a stake of 10,179 shares — an estimated $811K sold.

J. Goldman & Co first reported a position in RVMD in Q3 2023 and held it in 6 quarters. The position peaked at $1.15M in Q4 2024. 514 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

J. Goldman & Co reported no remaining Revolution Medicines position as of Q1 2026 after selling out during the quarter.
J. Goldman & Co sold 10,179 Revolution Medicines shares in Q1 2026, an estimated $811K.
J. Goldman & Co first reported a position in Revolution Medicines in Q3 2023 and held it in 6 quarters.
J. Goldman & Co's Revolution Medicines position peaked at $1.15M in Q4 2024.
514 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.